An interventional study of exercise in Breast Cancer and Behcet Disease, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 65 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
gryrotonic training may be a good exercise modality in Behcet-diseased elders with breast cancer
forty Behcet-diseased elders with breast cancer will randomy divide into group I (receive gyrotonic exercise three session weekly for 12 week) or group II (wait list)
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's planned enrollment of 40 is below the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
twenty Behcet-diseased elders who survived from breast cancer will receive gyrotonic exercise three session weekly for 12 week. the session will 45 min
Behavioral: exercise
twenty Behcet-diseased elders who survivied from breast cancer will be wait list for 12 weeks
twnety Behcet-diseased elders who survived from breast cancer will receive gyrotonic exercise three session weekly for 12 week. the session will last for 45 min
Short Physical Performance Battery
the total score will be calcualted
Time frame: it will be measured after 12 weeks
Dual task gait speed
this task assess gait speed
Time frame: It will be measured after 12 weeks
Four-square step test
it is fucntional balnce test
Time frame: It will be measured after 12 weeks
grip strenghts
it is a measure of grip strenghths in dominant hand
Time frame: It will be measured after 12 weeks
time up- and go testing
it is a measure of fall risk
Time frame: It will be measured after 12 weeks
sit-to-stand 30-second testing
asess number of repteations of sit-to-staning in 30 seconds
Time frame: It will be measured after 12 weeks
six minute walking testingg
distance covered by subject in six minutes wil be assessed
Time frame: It will be measured after 12 weeks
10-meters walking testing
time covered for walking for ten meter will be assessed
Time frame: It will be measured after 12 weeks
trunk-flexor McGill core endurance test
this test will assess endurance of trunk flexors
Time frame: It will be measured after 12 weeks
trunk-extensor McGill core endurance test
this test will assess endurance of trunk extensors
Time frame: It will be measured after 12 weeks
right-lateral-trunk-bending McGill core endurance test
this test will assess endurance of right lateral trunk bendors
Time frame: It will be measured after 12 weeks
left-lateral-trunk-bending McGill core endurance test
this test will assess endurance of left lateral trunk bendors
Time frame: It will be measured after 12 weeks
arm flexion in thrity seconds
it will assess numbers (repeations) of arm flexion in thirty second
Time frame: It will be measured after 12 weeks
maximal nubmer of push up
this will assess maximal number of performed psh ups in speciifc time
Time frame: It will be measured after 12 weeks
behcet disease quality of life
questioanire that will assess life quality in behcet disease (total score will be estiamted)
Time frame: It will be measured after 12 weeks
total score of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it is a questioaire asess quality of life
Time frame: It will be measured after 12 weeks
physical fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it is a questioaire asess physical fucntion related quality of life
Time frame: It will be measured after 12 weeks
role fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it is a questioaire asess role fucntion related quality of life
Time frame: It will be measured after 12 weeks
emotional fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it is a questioaire asess emotional fucntion related quality of life
Time frame: It will be measured after 12 weeks
cognitive fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it is a questioaire asess cognitive fucntion related quality of life
Time frame: It will be measured after 12 weeks
social fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it is a questioaire asess social fucntion related quality of life
Time frame: It will be measured after 12 weeks
fatigue fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it is a questioaire asess fatigue
Time frame: It will be measured after 12 weeks
nausea-vomiting subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it is a questioaire asess nausea-vomiting
Time frame: It will be measured after 12 weeks
pain subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it will assess pain
Time frame: It will be measured after 12 weeks
dyspnea subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it will assess dyspnea
Time frame: It will be measured after 12 weeks
insomnia subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it will assess insomnia
Time frame: It will be measured after 12 weeks
appetite-loss subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it will assess appetite loss
Time frame: It will be measured after 12 weeks
constipation subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it will assess constipation
Time frame: It will be measured after 12 weeks
diarrhea subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it will assess diarrhea
Time frame: It will be measured after 12 weeks
financial difficulties subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
it will assess financial difficulties
Time frame: It will be measured after 12 weeks
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.